What drove the pre‑market move in IBRX stock today?

The pre‑market move followed a Q4 beat: **$38.29M** in revenue and an adjusted EPS loss of **$0.06** versus consensus **-$0.08**. ANKTIVA sales and fresh commercial partnerships were the primary drivers.

How does Meyka AI rate IBRX stock and why?

Meyka AI rates IBRX with a score out of 100 at **74.30 (B+ — BUY)**. The grade weights benchmark and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus. Grades are informational only.

What price targets and forecasts should investors watch for IBRX stock?

Analyst consensus averages **$12.60**, a bull view cites **$23.00**, and Meyka AI's model projects **$2.19** one year out. Compare these with current **$11.55** and treat forecasts as projections, not guarantees.

When is the next earnings event that could move IBRX stock?

ImmunityBio’s next earnings announcement is scheduled for **March 2, 2026**. Management commentary and updated unit sales for ANKTIVA will be key market catalysts.

US Stocks

IBRX ImmunityBio NASDAQ pre-market up on Q4 beat 25 Feb 2026: ANKTIVA outlook

ByDanny Kontos February 25, 2026February 25, 2026

IBRX stock is trading pre-market at $11.55 on 25 Feb 2026 after ImmunityBio reported a Q4 revenue and EPS beat. The company posted $38.29 million in Q4 revenue and an adjusted loss per share of $0.06, beating consensus by $0.02. Investors are focused on ANKTIVA commercial traction and near-term regulatory milestones ahead of the March 2, 2026 earnings call. This earnings spotlight reviews the numbers, valuation, analyst views, and what drives price action in the United States NASDAQ session.